Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons.
暂无分享,去创建一个
Susan Mehle | C. Simonelli | Kathleen K. Killeen | Christine Simonelli | Kathleen Killeen | Leah Swanson | S. Mehle | Leah A Swanson
[1] S. Bonnick. Monitoring osteoporosis therapy with bone densitometry: a vital tool or regression toward mediocrity? , 2000, The Journal of clinical endocrinology and metabolism.
[2] O. Johnell,et al. Cost-Effectiveness of Preventing Hip Fracture in the General Female Population , 2001, Osteoporosis International.
[3] S. Boonen,et al. The Economic Cost of Hip Fractures Among Elderly Women: A One-Year, Prospective, Observational Cohort Study with Matched-Pair Analysis , 2001, The Journal of bone and joint surgery. American volume.
[4] S. Adami,et al. Alendronate for the Treatment of Osteoporosis in Men , 2001, Calcified Tissue International.
[5] D. Hosking,et al. Colles' Fracture of the Wrist as an Indicator of Underlying Osteoporosis in Postmenopausal Women: A Prospective Study of Bone Mineral Density and Bone Turnover Rate , 1998, Osteoporosis International.
[6] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[7] O Johnell,et al. How well can a previous fracture indicate a new fracture? A questionnaire study of 29,802 postmenopausal women. , 1998, Acta orthopaedica Scandinavica.
[8] E L Hannan,et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. , 2001, JAMA.
[9] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[10] P. Benum,et al. Colles' fracture as an indicator of increased risk of hip fracture. An epidemiological study. , 1987, Annales chirurgiae et gynaecologiae.
[11] R. Rizzoli,et al. Weekly administration of alendronate: rationale and plan for clinical assessment. , 2000, Clinical therapeutics.
[12] J. Berlin,et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.
[13] G E Dallal,et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.
[14] D. Kiel,et al. Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis , 2000, Aging.
[15] J A Stevens,et al. Reducing falls and resulting hip fractures among older women. , 2000, Home care provider.
[16] T. Abbott,et al. Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] Mark A Pereira,et al. Physical Activity, Falls, and Fractures Among Older Adults: A Review of the Epidemiologic Evidence , 2000, Journal of the American Geriatrics Society.
[18] S. Cummings,et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. , 1999, Arthritis and rheumatism.
[19] S. Cummings,et al. Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.
[20] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[21] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[22] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[23] E. E. Hajcsar,et al. Investigation and treatment of osteoporosis in patients with fragility fractures. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[24] E. Barrett-Connor,et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. , 1997, Archives of internal medicine.
[25] M. Erlandsen,et al. Occurrence and incidence of the second hip fracture. , 1993, Clinical orthopaedics and related research.
[26] D. Kiel,et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .
[27] J. Bilezikian,et al. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. , 1999, The Journal of clinical endocrinology and metabolism.
[28] J. Glowacki,et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. , 1999, JAMA.
[29] P Kannus,et al. Prevention of hip fracture in elderly people with use of a hip protector. , 2000, The New England journal of medicine.
[30] Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. , 2000, The Journal of clinical endocrinology and metabolism.
[31] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[32] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[33] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[34] M S Calvo,et al. Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.